Journal
CLINICA CHIMICA ACTA
Volume 342, Issue 1-2, Pages 1-12Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.cccn.2003.12.008
Keywords
S100 beta; BBB (blood-brain barrier); blood-CSF barrier; endothelium; cerebral ischemia; MRI (magnetic resonance imaging); neurological disorders; NSE (neuron-specific enolase); TTR (transthyretin); neurodiagnostic tools
Categories
Funding
- NHLBI NIH HHS [2R01 HL51614] Funding Source: Medline
- NINDS NIH HHS [R01 NS38195, R01 NS 43284] Funding Source: Medline
Ask authors/readers for more resources
Neurological diseases are often associated with cerebrovascular dysfunction and changes in blood-brain barrier (BBB) function. This is important for two seemingly conflicting reasons. On the one hand, a leaky BBB may lead to brain disease by allowing extravasation of cells and molecules normally segregated in the periphery, while on the other hand an intact BBB may hamper drug delivery to the ailing brain. Under both circumstances, it would be desirable to follow closely over time BBB tightness. Several lines of evidence have suggested that the astrocytic protein S100beta is a potentially useful peripheral marker of BBB permeability. Other markers of brain-to-blood barriers have been recently discovered by a proteomic approach. These proteins are virtually absent in normal blood, appear in serum from patients with cerebral lesions, and can be easily detected. We will present clinical and laboratory evidence supporting the use of these markers as modem neurodiagnostic tools. (C) 2004 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available